Nxera reports positive outcomes for daridorexant Phase III insomnia study

​Nxera Pharma has announced positive top-line results from its Phase III study of daridorexant 50 mg, aimed at treating insomnia in adult and elderly patients in South Korea.

The post Nxera reports positive outcomes for daridorexant Phase III insomnia study appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.